Error loading player: No playable sources found

64247

Parallel Session 8: Approaches to Decentralized Manufacturing

Date
June 28, 2023
This product is not available for individual purchase, but it is available as part of the following products:
Thumbnail for CGTP Summit 2023 / Cell and Gene Therapy Products Symposium 2023
The Cell and Gene Therapy Products (CGTP) Symposium: Manufacturing, Quality and Regulatory Considerations enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products…

Decentralized manufacturing involves the use of manufacturing units that can be deployed to multiple locations and in cases, to sites close to the patients. This new manufacturing concept can bring benefits over more traditional, central manufacturing, allowing, for instance, a production adaptable to demand or a more agile and flexible reaction to  public health emergencies. In the case of cell and gene therapies, many are highly personalized or have very short shelf-lives, features that could benefit from being manufactured close to the patients. 




Decentralized manufacturing presents new regulatory challenges since it requires a shift away from existing frameworks that are designed to meet the regulatory expectations for large-scale centralized manufacture. 




This session will bring together regulators and manufacturers with the objective of reviewing the different decentralized manufacturing approaches (e.g. distributed vs point of care) and identify some of the regulatory adaptations needed. The session will also discuss proposals to fulfil manufacturing and control challenges on a decentralized scenario, such as comparability between (potentially) many manufacturing sites, or carrying out complex testing (e.g. potency).




Session Speakers:




Decentralised and Point of Care Manufacturing - A UK Perspective 

Ian Rees, Retired, MHRA




Distributed Manufacturing for Cell Therapies: Regulatory Challenges and Solutions

Gülbengü Yüksel, Tigen Pharma SA




Attaining Worldwide Standardization Within A Decentralized Framework 

Chaya Mazouz, Orgenesis Inc.




Additional Panelists:




Johnny Lam, CBER, FDA

Marcos Timón, AEMPS

Related Products

Thumbnail for Parallel Session 7: Unique Challenges of Stability Testing for Cell and Gene Therapy Products
Parallel Session 7: Unique Challenges of Stability Testing for Cell and Gene Therapy Products
Cell and Gene Therapy programs are progressing from early academic settings to commercial manufacturing at increasingly faster pace and in greater numbers. These therapies are complex, difficult to manufacture in large quantities, and involve many bespoke technologies to make, test and release…
Thumbnail for Plenary Session 5: Challenges with Incoming Materials - Raw, Starting, Ancillary, etc.
Plenary Session 5: Challenges with Incoming Materials - Raw, Starting, Ancillary, etc.
Raw material selection decisions early in the development of ATMPs are crucial and can impact the final product quality and ultimately patient safety…
Thumbnail for Keynote Presentation
Keynote Presentation
Gene Therapy Drug Development for Ultra-Rare Disease: Challenges & Opportunities